Eric F. Morand

246 Clayton Rd
Clayton, VIC 3168, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 294 publications

Longitudinal comparison of treat-to-target states and clinical outcomes in patients with late-onset versus early-onset systemic lupus erythematosus.

Longitudinal comparison of treat-to-target states and clinical outcomes in patients with late-onset versus early-onset systemic lupus erythematosus.

Journal: The Journal of rheumatology

Published: September 01, 2026

Reversible temporal artery halo sign in polymerase chain reaction-confirmed herpes zoster ophthalmicus without corticosteroid exposure.

Reversible temporal artery halo sign in polymerase chain reaction-confirmed herpes zoster ophthalmicus without corticosteroid exposure.

Journal: Rheumatology advances in practice

Published: August 12, 2026

PROducing More Evidence to Reduce Glucocorticoids in Systemic Lupus Erythematosus: Putting Patient-Reported Outcomes in the Picture.

PROducing More Evidence to Reduce Glucocorticoids in Systemic Lupus Erythematosus: Putting Patient-Reported Outcomes in the Picture.

Journal: The Journal of rheumatology

Published: July 01, 2026

Systemic lupus erythematosus: Phase 2 trials to watch in 2026.

Systemic lupus erythematosus: Phase 2 trials to watch in 2026.

Journal: Med (New York, N.Y.)

Published: May 22, 2026

High disease activity persists in adults with childhood-onset lupus.

High disease activity persists in adults with childhood-onset lupus.

Journal: Lupus science & medicine

Published: April 28, 2026

Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes.

Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes.

Journal: RMD open

Published: February 04, 2026

Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.

Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.

Journal: Arthritis research & therapy

Published: January 14, 2026

Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.

Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.

Journal: Lupus science & medicine

Published: December 16, 2025

Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control Study.

Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control Study.

Journal: ACR open rheumatology

Published: December 15, 2025

Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study.

Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study.

Journal: Arthritis research & therapy

Published: December 10, 2025

Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrual.

Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrual.

Journal: Arthritis care & research

Published: December 05, 2025

Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials.

Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials.

Journal: Lupus science & medicine

Published: November 13, 2025

Showing 1-12 of 294

Last Updated: 09/26/2026